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Objective: To assess esophageal involvement (EI) in juvenile localized scleroderma (JLS)
population and the possible association between this gastrointestinal manifestation and
demographic data, clinical features, laboratory exams, treatments and outcomes.
Methods: For a period of 30 years, 5881 patients with rheumatic diseases were followed in our
Pediatric Rheumatology Division. EI was deﬁned by the presence of symptoms (solid/liquid
dysphagia, heartburn, esophageal regurgitation, nausea/vomiting and epigastralgia) and
conﬁrmed by at least one EI exam abnormality: barium contrast radiography, upper gas-
trointestinal endoscopy and 24-hour esophageal pH-monitoring.
Results: JLS was observed in 56/5881 patients (0.9%), mainly linear morphea subtype. EI
was  observed in 23/56(41%) of JLS patients. Eight(35%) of 23 EI patients with JLS were
symptomatic and presented heartburn(5/8), solid and liquid dysphagia(3/8), nausea and epi-
gastralgia(1/8). The frequency of any cumulative extracutaneous manifestations (calcinosis,
arthritis/arthralgia, central nervous system, interstitial pneumonitis, mesangial nephritis
and/or arrhythmia) was signiﬁcantly higher in JLS patients with EI compared to those with-
out  this complication (56% vs. 24%, p = 0.024). No differences were evidenced in demographic
data, JLS subtypes and in each extracutaneous manifestation in both groups (p > 0.05). The
frequency of methotrexate use was signiﬁcantly higher in JLS patients with EI compared
to  those without (52% vs. 12%, p = 0.002). Autoantibody proﬁle (antinuclear antibodies, anti-
SCL-70, rheumatoid factor, anticentromere, anti-cardiolipin, anti-Ro/SSA and anti-La/SSB)
was similar in both groups (p > 0.05).
Conclusions: Our study demonstrated that EI was frequently observed in JLS patients, mainly
in  asymptomatic patients with linear subtype. EI occurred in JLS patients with other extra-tions and required methotrexate therapy.cutaneous manifestaPlease cite this article in press as: Valões CC, et al. Esophageal abnormalities in juvenile localized scleroderma: is it associated with other
extracutaneous manifestations? Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.011
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Anormalidades  esofágicas  na  esclerodermia  localizada  juvenil:
associac¸ão  com  outras  manifestac¸ões extracutâneas?
Palavras-chave:
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Esôfago
Metotrexato
Crianc¸as
r  e  s  u  m  o
Objetivo: Avaliar o envolvimento do esôfago (EE) na populac¸ão com esclerodermia local-
izada juvenil (ELJ) e a possível associac¸ão entre essa manifestac¸ão gastrointestinal e dados
demográﬁcos, características clínicas, exames laboratoriais, tratamentos e desfechos.
Métodos: Durante 31 anos, 5.881 pacientes com doenc¸as reumáticas foram acompanhados
em  nossa Divisão de Reumatologia Pediátrica. O EE foi deﬁnido pela presenc¸a  de sintomas
(disfagia para sólidos/líquidos, azia, regurgitac¸ão esofágica, náuseas/vômitos e epigastral-
gia) e conﬁrmado com pelo menos um exame que revelou EE: radiograﬁa contrastada com
bário, endoscopia digestiva alta e pHmetria esofágica de 24 horas.
Resultados: Observou-se ELJ em 56/5.881 pacientes (0,9%), principalmente do subtipo morfeia
linear. O EE foi observado em 23/56 (41%) dos pacientes com ELJ. Oito (35%) dos 23 pacientes
com  ELJ com EE eram sintomáticos e apresentavam azia (5/8), disfagia para sólidos e
líquidos (3/8), náuseas e epigastralgias (1/8). A frequência de quaisquer manifestac¸ões extra-
cutâneas cumulativas (calcinose, artrite/artralgia, envolvimento do sistema nervoso central,
pneumonite intersticial, nefrite mesangial e/ou arritmias) foi signiﬁcativamente maior em
pacientes com ELJ com EE em comparac¸ão com aqueles sem essa complicac¸ão (56% vs. 24%,
p  = 0,024). Não foi evidenciada diferenc¸a nos dados demográﬁcos, subtipos de ELJ e quaisquer
manifestac¸ões extracutâneas entre os grupos (p > 0,05). A frequência de uso de metotrexato
foi  signiﬁcativamente maior em pacientes com ELJ com EE em comparac¸ão com aqueles
sem EE (52% vs. 12%, p = 0,002). O perﬁl de autoanticorpos (anticorpos antinucleares, anti-
SCL-70, fator reumatoide, anticentrômero, anticardiolipina, anti-Ro/SSA e anti-La/SSB) foi
semelhante nos dois grupos (p > 0,05).
Conclusões: Este estudo demonstrou que o EE foi frequentemente observado em pacientes
com ELJ, principalmente naqueles assintomáticos com o subtipo linear da doenc¸a. O EE
ocorreu em pacientes com ELJ com outras manifestac¸ões extracutâneas e exigiu tratamento
com metotrexato.
© 2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Juvenile scleroderma is a rare autoimmune disease, charac-
terized by skin inﬂammation and ﬁbrosis lesions, and occurs
before the age of 18.1–4 This condition comprises two major
types in children and adolescents: juvenile localized sclero-
derma (JLS) and juvenile systemic sclerosis (JSS).1,5,6
Manifestations are mainly limited to the skin and sub-
dermal tissues in JLS patients, whereas internal organs are
frequently affected in JSS patients.1,5 Extracutaneous manifes-
tations have been reported in up to 25% of JLS patients and are
mainly characterized by musculoskeletal involvement, partic-
ularly arthritis and tenosynovitis.7
Esophageal involvement (EI) has been described as fre-
quent extracutaneous manifestations in JSS.7–10 This involve-
ment has been studied in children and adolescents with JLS,
however it is usually limited to case reports or case series.5–12
To our knowledge there are no studies that evaluated solely
JLS patients comparing patients with and without EI.
Therefore, the aim of this study was to assess the preva-
lence of EI in JLS population, and the possible associationsPlease cite this article in press as: Valões CC, et al. Esophageal abnorma
extracutaneous manifestations? Rev Bras Reumatol. 2016. http://dx.doi.or
between this gastrointestinal manifestation and demographic
data, clinical features, laboratory exams, treatments and out-
comes.C BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Methods
This was a retrospective study carried out at the Pediatric
Rheumatology Unit of a tertiary University Hospital, Sao Paulo
city, Brazil. For a period of 31 years (1983–2014), 5881 patients
with pediatric rheumatic diseases were followed up in the
Pediatric Rheumatology Unit. The inclusion criteria were con-
secutive patients with JLS diagnosis followed from 1986 to
2014. Overlap syndromes with other autoimmune diseases
were systematically excluded.
Demographic data and clinical features were collected
from medical charts. The clinical JLS subtypes were deﬁned
according to Padua criteria 2004, and classiﬁed in 5 subtypes:
circumscribed morphea, linear scleroderma, generalized mor-
phea, pansclerotic morphea and mixed morphea.4
EI was deﬁned by the presence of gastrointestinal
symptoms (solid/liquid dysphagia, heartburn, esophageal
regurgitation, nausea/vomiting and epigastralgia) and con-
ﬁrmed by at least one laboratory test abnormality: barium
contrast radiography, upper gastrointestinal endoscopy and
24-h esophageal pH-monitoring. Extracutaneus manifesta-lities in juvenile localized scleroderma: is it associated with other
g/10.1016/j.rbre.2016.09.011
tions related to JLS, such as calcinosis, articular, central
nervous system, pulmonary, cardiac and renal involvements,
and treatments were also systematically recorded.
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Table 1 – Demographic data, clinical JLS subtypes and other extracutaneous manifestations in 56 JLS patients with and
without esophageal involvement.
Variables JLS with esophageal
involvement (n = 23)
JLS  without esophageal
involvement (n = 33)
p
Demographic data
Age at JLS onset, years 3.5 (2.8–7.4) 5.0 (3.0–9.8) 0.255
Age at diagnosis, years 5.6 (3.7–9.7) 7.15 (5.3–10) 0.253
Time between JLS onset and diagnosis, years 1.3 (1.0–4.0) 1.0 (0.4–2.0) 0.204
Female gender 19  (83) 28 (85) 1.000
JLS subtypes
Circumscribed morphea 3 (13) 5 (15) 1.000
Linear scleroderma 15 (65) 22 (67) 1.000
Generalized morphea 3 (13) 3 (9) 0.600
Mixed morphea 2 (9) 3 (9) 1.000
Cumulative extracutaneous manifestations
At least one 13 (56) 8 (24) 0.024
Raynaud phenomenon 0 (0) 0 (0) 1.000
Calcinosis 1 (4) 0 (0) 0.400
Arthritis/arthralgia 7 (30) 5 (15) 0.190
CNS involvement 1 (4) 1 (3) 1.000
Interstitial pneumonitis 3 (13) 1  (3) 1.000
Mesangial nephritis 0  (0) 1  (3) 1.000
Cardiac involvement 1 (4) 0 (0) 0.400
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JLS, juvenile localized scleroderma; CNS, central nervous system.
The serum antibody proﬁle included antinuclear anti-
ody (ANA, including assessment of anticentromere anti-
ody, by indirect immunoﬂuorescence), anti-SCL-70 [DNA-
opoisomerase1 by Enzyme Linked Immuno Sorbent Assay
ELISA)], rheumatoid factor (RF, by immunonephelometry),
nticardiolipin antibodies (ACL IgM and IgG by ELISA), anti-
o/SSA and anti-La/SSB (by ELISA), and anti-RNP by ELISA. Nail
old capillaroscopy was also performed at JLS diagnosis.
tatistical  analysis
esults were presented as number (frequency) and median
range) or mean ± standard deviation. JLS patients were
ivided according to the presence or absence of EI, and cate-
orical variables were compared using Fisher’s exact test and
ontinuous variables using Mann–Whitney U-test or t-test, as
ndicated. The statistical signiﬁcance was set at p < 0.05.
esults
LS was observed in 56/5881 (0.9%). EI was evidenced in 23/56
41%) of JLS patients. EI was observed in 6/23 (26%) before one
ear of JLS diagnosis and 17/23 (74%) after one year of JLS diag-
osis. EI was present in 16/23 (69%) before two years of JLS
iagnosis and 7/23 (30%) after two years of diagnosis.
EI was diagnosed by upper gastrointestinal endoscopy in
/23 (17%), barium contrast radiography in 20/23 (87%) and
4-h esophageal pH-monitoring in 0/1 (0%) of JLS patients. Gas-
roesophageal reﬂux diagnosis was performed by radiographicPlease cite this article in press as: Valões CC, et al. Esophageal abnorma
extracutaneous manifestations? Rev Bras Reumatol. 2016. http://dx.doi.or
arium swallow in 16/23 (69%) of JSL patients. Fifteen of 23 EI
atients with JLS (65%) were asymptomatic. Heartburn and
sophageal regurgitation was only observed in 1/15 patient
previously asymptomatic) after two years of follow-up.Eight (35%) of 23 EI patients with JLS were symptomatic
and presented heartburn (5/8), solid and liquid dysphagia (3/8),
and nausea and epigastralgia (1/8). Vomiting was not reported
by any of the patients. Proton pump inhibitors were used in
4/8 JLS patients, histamine-2 receptor antagonist in 3/8 and
prokinetic drugs in 4/8.
Regarding outcomes, esophageal imaging abnormalities
were revaluated in 17/23 JLS patients with EI after one year of
the previous exam, and 12/17 had maintenance of esophageal
imaging. None of them required surgical intervention. None of
them presented esophagus stenosis, neither Barrett’s esoph-
agus nor esophageal adenocarcinoma.
Demographic data, clinical subtypes and extracutaneous
manifestations in JLS patients with and without EI are shown
in Table 1. The frequency of any cumulative extracutaneous
manifestations was signiﬁcantly higher in JLS patients with EI
compared to patients without this complication (56% vs. 24%,
p = 0.024). No differences were evidenced in each extracuta-
neous manifestations in both groups (p > 0.05). The median age
of diagnosis and disease duration were similar in both groups,
as well as the frequency of circumscribed morphea, linear scle-
roderma, generalized morphea and mixed morphea (p > 0.05,
Table 1).
Laboratory exams and treatments in JLS patients with
and without EI are shown in Table 2. The frequency of
methotrexate use was signiﬁcantly higher in JLS patients with
EI compared to patients without this complication (52% vs.
12%, p = 0.002). The median of blood eosinophils was  similar in
both groups (p > 0.05), likewise the frequency of autoantibody
proﬁle (ANA, anti-SCL-70, RF, anticentromere, ACL IgG andlities in juvenile localized scleroderma: is it associated with other
g/10.1016/j.rbre.2016.09.011
IgM, anti-Ro/SSA, anti-La/SSB and anti-RNP) (p > 0.05, Table 2).
Skin lesion biopsy was performed in 38/56 (68%) of
JLS patients and revealed lymphohistiocytic inﬂammatory
inﬁltrate with ﬁbroblasts or ﬁbrosis in dermis substituting
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Table 2 – Laboratory exams and treatments in 56 JLS patients with and without esophageal involvement.
Variables JLS with esophageal
involvement (n = 23)
JLS  without esophageal
involvement (n = 33)
p
Laboratory exams at diagnosis
ESR, mm/1st h 11 (6.5–19.5) 17 (8.7–30.2) 0.173
Blood eosinophils, mm3 279 (200–350) 196 (106.5–478.5) 0.314
Cumulative autoantibodies
ANA 8/22  (37) 9/29 (31) 0.760
Rheumatoid factor 1/10 (10) 1/14 (7) 1.000
Anti-SCL 70 1/20 (5) 1/19 (5) 1.000
Anti-centromere 0/22 (0) 0/29 (0) 1.000
Anti-Ro/SSA 1/9 (11) 1/9 (11) 1.000
Anti-La/SSB 2/9 (22) 0/9 (0) 0.470
Anti-RNP 1/16 (6) 0/26 (0) 0.381
Anticardiolipin IgM/IgG 0/10 (0) 0/15 (0) 1.000
Normal capilaroscopy 5/5 (100) 4/4 (100) 1.000
Cumulative treatment
Methotrexate 12 (52) 4 (12) 0.002
Oral corticosteroid 5 (22) 2 (6) 0.110
Colchicine 7 (30) 6 (18) 0.340
D-penicillamine 4 (17) 3  (9) 0.420
ate; A
Results are presented in median (range) and n (%).
JLS, juvenile localized scleroderma; ESR, erythrocyte sedimentation r
adipose panicle compatible with scleroderma histology in all
38 patients.
Discussion
Our study demonstrated that EI was frequently observed at
diagnosis in JLS patients. EI occurred in JLS patients with other
extracutaneous manifestations and required methotrexate
therapy. This gastrointestinal manifestation was observed
mainly in asymptomatic patients with linear subtype.
The advantage of the present study was the inclusion of a
JLS population of a University Hospital using standardized def-
inition of these localized scleroderma subtypes.8 In addition,
JLS patients followed in our service had been submitted to a
periodic exams evaluation annually, which included screening
for esophageal, pulmonary and heart involvements. Indeed
EI was observed in one third of our JLS patients two years
after diagnosis, reinforcing the relevance of this longitudinal
assessment.
EI has been rarely studied in JLS patients.5–12 Guariso et al.,5
reported EI in 8/14 (57%) of JLS patients, where only three
of them were asymptomatic, contrasting with our study that
almost two  thirds were asymptomatic. Zulian et al.,7 reported
gastroesophageal reﬂux (preferably assessed by barium con-
trast radiography or 24-h intraesophageal pH monitoring) in
1.6% of JLS patients. In this study the diagnosis of gastroesoph-
ageal reﬂux was performed only in symptomatic patients.
Barium contrast radiography was used to exclude
esophageal anatomic abnormalities, however this exam
cannot differentiate between non-pathological gastroesoph-
13Please cite this article in press as: Valões CC, et al. Esophageal abnorma
extracutaneous manifestations? Rev Bras Reumatol. 2016. http://dx.doi.or
ageal reﬂux and gastroesophageal reﬂux disease. In our
study none of our JLS patients were infants, suggesting that
this abnormality may be related to the scleroderma, as also
previously reported.7NA, antinuclear autoantibodies; CRP, C reactive protein.
An international study reported extracutaneous manifes-
tations in 22% of JLS patients, and multiple extracutaneous
involvements (more than one) in 4% of these patients.
In this multicenter study, the main extracutaneous man-
ifestations were articular (47%), neurologic (17%), and
gastrointestinal (6%) and respiratory (3%) involvements that
were rarely reported.7 The high frequency of extracutaneous
manifestations (31/56 – 55%), mainly EI, arthritis/arthralgia
and interstitial pneumonitis observed in this study, may
be related to the fact that our Hospital usually follows-up
patients with moderate/severe chronic diseases.
Blood eosinophils count and autoantibody proﬁle did not
allow differentiating between JLS patients with and without
EI. Additionally, the most frequent autoantibodies in our JLS
patients with esophagus involvement was ANA, as also previ-
ously reported.4,5,7,8
The treatment of general EI, that involves gastroesopha-
geal reﬂux disease and esophagitis, includes lifestyle changes,
pharmacologic therapies and surgical intervention13 and
seem not to be different from systemic sclerosis in adults
with EI.14,15 In our cohort, standard therapy was introduced
for symptomatic patients with adequate response and with-
out esophagus complications. Furthermore, recent studies
reported that use of methotrexate was beneﬁcial for JLS
therapy.4,8 The high frequency of this immunosuppressive
agent used in our JLS patients with EI may be due to the disease
severity observed herein.
The main limitation of this study was the retrospective
design with possible missing data, and the employment of
different treatments in JLS patients throughout the years.
Currently, impedance pHmetry is considered to be thelities in juvenile localized scleroderma: is it associated with other
g/10.1016/j.rbre.2016.09.011
gold standard for the diagnosis of gastroesophageal reﬂux
disease.13 However, impedance pHmetry and esophageal
manometry were not performed in all of our patients, since
these exams were made available at our service only recently.
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In conclusion, EI was frequently observed in the ﬁrst
wo years in JLS patients, mainly asymptomatic patients
ith linear scleroderma subtype. EI occurred in JLS patients
ith other extracutaneous manifestations and required
ethotrexate therapy. This study reinforces the need to screen
or other organs and systems involvements in JLS patients
eriodically.
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